Cidara Therapeutics, Inc. (CDTX)

Market Cap	1.08B
Revenue (ttm)	302,000
Net Income (ttm)	-182.98M
Shares Out	22.12M
EPS (ttm)	-20.89
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,157,429
Open	48.50
Previous Close	49.45
Day's Range	46.18 - 50.48
52-Week Range	10.14 - 56.83
Beta	1.10
Analysts	Strong Buy
Price Target	52.11 (+6.98%)
Earnings Date	Aug 12, 2025

About CDTX

Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company’s product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 15, 2015
• Employees: 38
• Stock Exchange: NASDAQ
• Ticker Symbol: CDTX
• Website: https://www.cidara.com

Financial Performance

In 2024, Cidara Therapeutics's revenue was $1.28 million, a decrease of -94.52% compared to the previous year's $23.28 million. Losses were -$169.83 million, 640.6% more than in 2023.

Analyst Forecast

According to 11 analysts, the average rating for CDTX stock is "Strong Buy." The 12-month stock price forecast is $52.11, which is an increase of 6.98% from the latest price.

Price Target

$52.11

(6.98% upside)

Analyst Consensus: Strong Buy